"Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors".
Cardiovascular and pulmonary disorders
Chemotherapy
Fatigue
Germ cell ovarian neoplasms
Long-term effects
Physical sequelae
Quality of life
Sex cord stromal tumors
Survivorship
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
26 Oct 2021
26 Oct 2021
Historique:
received:
06
03
2021
accepted:
11
10
2021
entrez:
27
10
2021
pubmed:
28
10
2021
medline:
12
2
2022
Statut:
epublish
Résumé
Germ cell tumors and sex cord stromal tumors are rare cancers of the ovary. They mainly affect young women and are associated with a high survival rate. The standard treatment mainly involves conservative surgery combined with chemotherapy [bleomycin, etoposide and cisplatin (BEP)] depending on the stage and the prognostic factors, as for testicular cancers. As reported in testicular cancer survivors, chemotherapy may induce sequelae impacting quality of life, which has not yet been evaluated in survivors of germ cell tumors and sex cord stromal tumors. The GINECO-VIVROVAIRE-Rare tumor study is a two-step investigation aiming to assess i) chronic fatigue and quality of life and ii) long-term side-effects of chemotherapy with a focus on cardiovascular and pulmonary disorders. Using self-reported questionnaires, chronic fatigue and quality of life are compared between 134 ovarian cancer survivors (cancer-free ≥2 years after treatment) treated with surgery and chemotherapy and 2 control groups (67 ovarian cancer survivors treated with surgery alone and 67 age-matched healthy women). Medical data are collected from patient records. In the second step evaluating the long-term side-effects of chemotherapy, a subgroup of 90 patients treated with chemotherapy and 45 controls undergo the following work-up: cardiovascular evaluation (clinical examination, non-invasive cardiovascular tests to explore heart disease, blood tests), pulmonary function testing, audiogram, metabolic and hormonal blood tests. Costs of sequelae will be also assessed. Patients are selected from the registry of the INCa French Network for Rare Malignant Ovarian Tumors, and healthy women by the 'Seintinelles' connected network (collaborative research platform). This study will provide important data on the potential long-term physical side-effects of chemotherapy in survivors of Germ Cell Tumors (GCT) and Sex Cord Stromal Tumors (SCST), especially cardiovascular and pulmonary disorders, and neurotoxicity. The identification of long-term side-effects can contribute to adjusting the treatment of ovarian GCT or SCST patients and to managing follow-up with adapted recommendations regarding practices and chemotherapy regimens, in order to reduce toxicity while maintaining efficacy. Based on the results, intervention strategies could be proposed to improve the management of these patients during their treatment and in the long term. This trial was registered at clinicaltrials.gov : 03418844 , on 1 February 2018. This trial was registered on 25 October 2017 under the unique European identification number (ID-RCB): 2017-A03028-45. Recruitment Status: Recruiting. Version n° 4.2 dated from Feb 19, 2021. Centre François Baclesse, 3 avenue du Général Harris, F-14076 Caen cedex 05, France.
Sections du résumé
BACKGROUND
BACKGROUND
Germ cell tumors and sex cord stromal tumors are rare cancers of the ovary. They mainly affect young women and are associated with a high survival rate. The standard treatment mainly involves conservative surgery combined with chemotherapy [bleomycin, etoposide and cisplatin (BEP)] depending on the stage and the prognostic factors, as for testicular cancers. As reported in testicular cancer survivors, chemotherapy may induce sequelae impacting quality of life, which has not yet been evaluated in survivors of germ cell tumors and sex cord stromal tumors. The GINECO-VIVROVAIRE-Rare tumor study is a two-step investigation aiming to assess i) chronic fatigue and quality of life and ii) long-term side-effects of chemotherapy with a focus on cardiovascular and pulmonary disorders.
METHODS
METHODS
Using self-reported questionnaires, chronic fatigue and quality of life are compared between 134 ovarian cancer survivors (cancer-free ≥2 years after treatment) treated with surgery and chemotherapy and 2 control groups (67 ovarian cancer survivors treated with surgery alone and 67 age-matched healthy women). Medical data are collected from patient records. In the second step evaluating the long-term side-effects of chemotherapy, a subgroup of 90 patients treated with chemotherapy and 45 controls undergo the following work-up: cardiovascular evaluation (clinical examination, non-invasive cardiovascular tests to explore heart disease, blood tests), pulmonary function testing, audiogram, metabolic and hormonal blood tests. Costs of sequelae will be also assessed. Patients are selected from the registry of the INCa French Network for Rare Malignant Ovarian Tumors, and healthy women by the 'Seintinelles' connected network (collaborative research platform).
DISCUSSION
CONCLUSIONS
This study will provide important data on the potential long-term physical side-effects of chemotherapy in survivors of Germ Cell Tumors (GCT) and Sex Cord Stromal Tumors (SCST), especially cardiovascular and pulmonary disorders, and neurotoxicity. The identification of long-term side-effects can contribute to adjusting the treatment of ovarian GCT or SCST patients and to managing follow-up with adapted recommendations regarding practices and chemotherapy regimens, in order to reduce toxicity while maintaining efficacy. Based on the results, intervention strategies could be proposed to improve the management of these patients during their treatment and in the long term.
TRIAL REGISTRATION
BACKGROUND
This trial was registered at clinicaltrials.gov : 03418844 , on 1 February 2018. This trial was registered on 25 October 2017 under the unique European identification number (ID-RCB): 2017-A03028-45. Recruitment Status: Recruiting.
PROTOCOL VERSION
METHODS
Version n° 4.2 dated from Feb 19, 2021.
TRIAL SPONSOR
UNASSIGNED
Centre François Baclesse, 3 avenue du Général Harris, F-14076 Caen cedex 05, France.
Identifiants
pubmed: 34702204
doi: 10.1186/s12885-021-08864-8
pii: 10.1186/s12885-021-08864-8
pmc: PMC8549373
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1147Subventions
Organisme : Fondation ARC pour la Recherche sur le Cancer
ID : PGA1*20160203900
Informations de copyright
© 2021. The Author(s).
Références
Sex Med. 2019 Dec;7(4):530-539
pubmed: 31501030
Rev Epidemiol Sante Publique. 2018 Mar;66 Suppl 2:S93-S99
pubmed: 29526356
Int J Gynecol Cancer. 2015 Nov;25(9):1593-8
pubmed: 26308607
Br J Cancer. 2013 Aug 20;109(4):891-6
pubmed: 23922115
Ann Oncol. 2013 Mar;24(3):749-55
pubmed: 23131388
Ann Oncol. 2011 Oct;22(10):2286-93
pubmed: 21878427
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Psychosom Res. 2008 Apr;64(4):363-71
pubmed: 18374735
J Natl Cancer Inst. 2007 Apr 4;99(7):533-44
pubmed: 17405998
J Clin Oncol. 2007 Jul 1;25(19):2792-7
pubmed: 17602084
Eur J Cancer Care (Engl). 2003 Mar;12(1):58-64
pubmed: 12641557
Gynecol Oncol. 1992 Apr;45(1):26-31
pubmed: 1376294
J Clin Oncol. 2002 Jan 1;20(1):73-80
pubmed: 11773156
Ann Oncol. 2002 Feb;13(2):229-36
pubmed: 11885999
Pharmacoeconomics. 2020 Apr;38(4):413-425
pubmed: 31912325
J Clin Oncol. 2012 Jan 20;30(3):300-7
pubmed: 22184390
Urol Oncol. 2015 Sep;33(9):399-406
pubmed: 25554583
Oncol Rep. 2010 Jan;23(1):247-53
pubmed: 19956889
Br J Cancer. 2009 Jun 16;100(12):1861-6
pubmed: 19455138
Support Care Cancer. 2020 Dec;28(12):5839-5849
pubmed: 32253602
Gen Hosp Psychiatry. 2016 Jan-Feb;38:21-5
pubmed: 26439320
Br J Cancer. 2013 Jul 9;109(1):60-7
pubmed: 23660945
Ann Oncol. 2017 Jun 1;28(6):1274-1279
pubmed: 28398524
Gynecol Oncol. 2019 Feb;152(2):346-352
pubmed: 30578004
Acta Oncol. 2007;46(4):417-32
pubmed: 17497308
J Natl Cancer Inst. 2010 Aug 4;102(15):1114-30
pubmed: 20585105
Support Care Cancer. 2012 Dec;20(12):3297-305
pubmed: 22549504
J Psychosom Res. 1995 Apr;39(3):315-25
pubmed: 7636775
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S42-7
pubmed: 25341579
Gynecol Oncol. 2015 Nov;139(2):324-9
pubmed: 26383829
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
Gynecol Oncol. 2017 Apr;145(1):148-153
pubmed: 28202195
Sleep Med. 2001 Jul;2(4):297-307
pubmed: 11438246
J Clin Oncol. 2009 Sep 1;27(25):4142-9
pubmed: 19636015
Med Oncol. 2014 Jul;31(7):43
pubmed: 24913808
Gynecol Obstet Fertil. 2009 Jul-Aug;37(7-8):627-32
pubmed: 19574079
J Natl Cancer Inst. 2009 Dec 16;101(24):1682-95
pubmed: 19940282
Ann Oncol. 2015 Oct;26(10):2133-40
pubmed: 26265167